Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib

Lapatinib, a dual tyrosine kinase inhibitor of ErbB1 and ErbB2, shows a clinical benefit in a subset of patients with advanced urothelial bladder cancer (UBC). We hypothesized that the corresponding gene, ERBB2, is affected by mutations in a subset of UBC and that these mutations impact ErbB2 functi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: de Martino, Michela, Zhuang, Dazhong, Klatte, Tobias, Rieken, Malte, Rouprêt, Morgan, Xylinas, Evanguelos, Clozel, Thomas, Krzywinski, Martin, Elemento, Olivier, Shariat, Shahrokh F
Natura: Artigo
Lingua:Inglês
Pubblicazione: Landes Bioscience 2014
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4128866/
https://ncbi.nlm.nih.gov/pubmed/24971884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.29687
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi